Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 2/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38664462 | 1.00 | DDB1 (0.34) | DDB1CRBNNFKB1NFKB2RELA | |
| SCHEMBL24687471 | 0.90 | DDB1 (0.33) | DDB1CRBNNFKB1NFKB2RELA | |
| SCHEMBL30617431 | 0.83 | DDB1 (0.38) | DDB1CRBNNFKB1NFKB2RELA | |
| SCHEMBL25070943 | 0.83 | DDB1 (0.38) | DDB1CRBNNFKB1NFKB2RELA | |
| SCHEMBL28903468 | 0.82 | DDB1 (0.35) | DDB1CRBNNFKB1NFKB2RELA | |
| SCHEMBL38663284 | 0.79 | CRBN (0.34) | DDB1CRBNIRAK4LMNAKCNA5 | |
| SCHEMBL24608436 | 0.76 | ALDH1A1 (0.38) | NFKB1NFKB2RELALMNAL3MBTL1 | |
| SCHEMBL24940770 | 0.76 | NAMPT (0.35) | NFKB1NFKB2RELAL3MBTL1NAMPT | |
| SCHEMBL22675491 | 0.75 | MEN1 (0.37) | NFKB1IRAK4LMNAKCNA5L3MBTL1 | |
| SCHEMBL23725248 | 0.75 | SSTR4 (0.36) | IRAK4KCNA5ALDH1A1TACR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | DDB1 14/4885CRBN 2080/4885NFKB1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.